Bajaj Healthcare Limited — Important, 30-01-2025: General Updates

Bajaj Healthcare Limited has received approval from the Drug Controller General of India (DCGI) to manufacture both the API and Drug Formulation of Pimavanserin, a 34 mg capsule indicated for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis. Pimavanserin, marketed globally as NUPLAZID®, is expected to generate over $1 billion in net sales in 2025, illustrating strong demand for this therapy. The company is also extending offers for manufacturing to several leading Indian pharmaceutical firms, facilitating product availability in the domestic market. This approval is viewed as a significant milestone, allowing Bajaj Healthcare to strengthen its position within the central nervous system segment and enhance healthcare solutions in India. The firm emphasizes its commitment to maintaining international quality standards throughout the manufacturing process.